R Abedini1, M Salehi1, V Lajevardi1, S Beygi1,2. 1. Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran. 2. National Elites Foundation of Iran, Tehran, Iran.
Abstract
BACKGROUND: Psoriasis is a chronic, immune-mediated inflammatory skin disease with many extracutaneous manifestations. Several recent studies have indicated an increased prevalence of nonalcoholic fatty liver disease (NAFLD) among patients with psoriasis. In the present study, we investigated the prevalence of NAFLD in a population of Iranian patients with psoriasis. METHODS: NAFLD was assessed and graded using ultrasonography in 123 patients with psoriasis and 123 healthy controls (HCs) matched by age, sex and body mass index (BMI). RESULTS: The prevalence of NAFLD was significantly higher in the psoriatic group compared with the HC group (65.6% vs. 35%, P < 0.01, OR = 3.53). Median NAFLD grade was significantly greater in patients with psoriasis compared with HCs (grade 2 vs. grade 1, P < 0.01). In patients with psoriasis, NAFLD was associated with a higher frequency of hypertension (16.5%), abnormal liver function test (LFT) results (16.4%) and metabolic syndrome (46.6%). Moreover, patients with psoriasis and NAFLD tended to have significantly higher values for BMI, waist circumference (WC), Psoriasis Activity and Severity Index (PASI), and levels of serum triglyceride, cholesterol, low-density lipoprotein and fasting blood sugar (FBS). Multivariate logistic regression revealed that WC, PASI, LFT abnormalities, hypertension and cigarette smoking were independent predictors of NAFLD grade. CONCLUSIONS: Our findings warrant a detailed assessment of metabolic comorbidities including NAFLD in patients with a primary diagnosis of psoriasis. Lifestyle modifications, including weight loss and smoking cessation, may be necessary for patients with psoriasis to decrease the risk and severity of NAFLD.
BACKGROUND:Psoriasis is a chronic, immune-mediated inflammatory skin disease with many extracutaneous manifestations. Several recent studies have indicated an increased prevalence of nonalcoholic fatty liver disease (NAFLD) among patients with psoriasis. In the present study, we investigated the prevalence of NAFLD in a population of Iranian patients with psoriasis. METHODS: NAFLD was assessed and graded using ultrasonography in 123 patients with psoriasis and 123 healthy controls (HCs) matched by age, sex and body mass index (BMI). RESULTS: The prevalence of NAFLD was significantly higher in the psoriatic group compared with the HC group (65.6% vs. 35%, P < 0.01, OR = 3.53). Median NAFLD grade was significantly greater in patients with psoriasis compared with HCs (grade 2 vs. grade 1, P < 0.01). In patients with psoriasis, NAFLD was associated with a higher frequency of hypertension (16.5%), abnormal liver function test (LFT) results (16.4%) and metabolic syndrome (46.6%). Moreover, patients with psoriasis and NAFLD tended to have significantly higher values for BMI, waist circumference (WC), Psoriasis Activity and Severity Index (PASI), and levels of serum triglyceride, cholesterol, low-density lipoprotein and fasting blood sugar (FBS). Multivariate logistic regression revealed that WC, PASI, LFT abnormalities, hypertension and cigarette smoking were independent predictors of NAFLD grade. CONCLUSIONS: Our findings warrant a detailed assessment of metabolic comorbidities including NAFLD in patients with a primary diagnosis of psoriasis. Lifestyle modifications, including weight loss and smoking cessation, may be necessary for patients with psoriasis to decrease the risk and severity of NAFLD.
Authors: Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield Journal: JAMA Dermatol Date: 2017-07-01 Impact factor: 10.282
Authors: Augusta Ortolan; Mariagrazia Lorenzin; Giulia Tadiotto; Francesco Paolo Russo; Francesca Oliviero; Mara Felicetti; Renata D'Incà; Marta Favero; Stefano Piaserico; Andrea Doria; Roberta Ramonda Journal: Clin Rheumatol Date: 2019-06-28 Impact factor: 2.980
Authors: Alexis Ogdie; Sungat K Grewal; Megan H Noe; Daniel B Shin; Junko Takeshita; Zelma C Chiesa Fuxench; Rotonya M Carr; Joel M Gelfand Journal: J Invest Dermatol Date: 2017-11-02 Impact factor: 8.551
Authors: Luigi Barrea; Paolo Emidio Macchia; Giovanni Tarantino; Carolina Di Somma; Elena Pane; Nicola Balato; Maddalena Napolitano; Annamaria Colao; Silvia Savastano Journal: J Transl Med Date: 2015-09-16 Impact factor: 5.531
Authors: Ivana Mikolasevic; Sandra Milic; Tamara Turk Wensveen; Ivana Grgic; Ivan Jakopcic; Davor Stimac; Felix Wensveen; Lidija Orlic Journal: World J Gastroenterol Date: 2016-11-21 Impact factor: 5.742